Compare Nasdaq100 ETF (QQQ) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nasdaq100 ETF vs 10X Genomics Inc — how do they compare? Nasdaq100 ETF trades at $750.6 (market cap $506.92B), while 10X Genomics Inc trades at $81.41 (market cap $10.07B). The key difference: Nasdaq100 ETF is far larger — about 50.3× 10X Genomics Inc's market cap, and Nasdaq100 ETF is trading nearer its 52-week high, 10X Genomics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nasdaq100 ETF for 162 Days and 10X Genomics Inc for 92 Days on average.
| QQQ | TXG | |
|---|---|---|
Market Cap | $506.92B | $10.07B |
Volume | 48,326,518 | 5,657,286 |
52-Week High | $759.66 | $97.74 |
52-Week Low | $558.34 | $11.48 |
Typical Hold Time | 162 Days | 92 Days |
Sector | — | Health |
Enterprise Value | — | $9.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QQQ trades at $749.24, down 1.12% with a bullish technical signal from moving averages. The ETF shows neutral oscillator readings and mixed analyst sentiment with a 50% buy/50% sell split. Recent news highlights QQQ's tech concentration and fee comparisons with competing ETFs, while broader market concerns about AI valuations and interest rates create headwinds.
The outlook remains cautiously optimistic given strong technical momentum, though elevated tech valuations and Federal Reserve policy pose risks. QQQ's innovation-focused portfolio offers growth exposure but requires monitoring of concentration risk in the technology sector amid market volatility.
TXG trades at $76.10, down 5.65% on the day, reflecting a bearish technical trend. The company reported revenue of $642.82M for 2025 with a net loss of $43.54M, though it has consistently beaten quarterly EPS estimates. Recent news highlights strong demand for its Atera spatial biology platform and a patent victory. The stock faces resistance near $77 and support at $72.
The outlook is mixed; strong product demand and improving margins offer upside, but persistent losses and high valuation ratios pose risks. Analyst consensus is divided, with a $74.30 price target slightly below the current price, indicating cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nasdaq100 ETF
The ETF is designed to track the performance of the securities and the stocks in the NASDAQ-100 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on QQQ →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
